Methergin

Methylergometrine Maleate, the active ingredient in Methergin, is an ergot alkaloid presented as an injectable solution for intramuscular and intravenous use. It is employed to prevent and treat postpartum hemorrhage and to control uterine atony in obstetric patients.

GNH USA supplies Methergin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Methergin acts on the uterine smooth‑muscle pathway to promote contraction and reduce bleeding.

Postpartum hemorrhage: helps prevent and treat excessive bleeding after delivery. Uterine atony: restores tone in a relaxed uterus to control hemorrhage. Obstetric surgery: supports uterine contraction during and after surgical procedures.

Methergin may cause a range of adverse reactions.

Common Side Effects: - Nausea and vomiting - Headache - Hypertension - Flushing or warmth sensation - Abdominal pain - Dizziness

Serious or Rare Side Effects: - Coronary artery spasm or myocardial ischemia - Severe hypertension or hypertensive crisis - Seizures - Pulmonary edema - Severe allergic reaction (anaphylaxis) - Thromboembolic events

Methergin requires careful monitoring in obstetric care. - Blood pressure monitoring: observe for hypertension during and after administration. - Cardiovascular risk: avoid in patients with known coronary artery disease. - Hypersensitivity: discontinue if signs of allergic reaction appear. - Use under obstetric supervision: ensure appropriate dosing and timing. - Contraindications: do not use in patients with known ergot sensitivity. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Methergin can interact with several drug classes.

Major Interactions (Avoid): - MAO inhibitors: risk of severe hypertensive crisis. - Other ergot derivatives: additive vasospasm and hypertension. - Sympathomimetic agents: excessive vasoconstriction.

Moderate Interactions (Monitor Closely): - Antihypertensive medications: may reduce efficacy of blood pressure control. - Calcium channel blockers: potential enhanced vasospasm. - Beta‑blockers: may alter cardiovascular response. - Antidepressants affecting serotonin: monitor for serotonergic effects. - NSAIDs: may increase risk of hypertension.